Buradasınız

Talasemi major tanisi olan hastalarda osteoporoz sikliginin degerlendirilmesi

Determination of osteoporosis frequency among the thalassemia major patients

Journal Name:

Publication Year:

DOI: 
10.2399/tahd.13.38247

Keywords (Original Language):

Abstract (2. Language): 
Objective: Thalassemia major is the heaviest form of the tha-lassemias. Anemia, hepatosplenomegaly, spinal deformities and osteoporosis can be seen in the patients with thalassemia major. Our aim is to detect the frequency of osteoporosis among the tha-lassemia major patients. Methods: Patients with diagnosis of thalassemia major were included in the study. Bone mineral density (BMD) scores (T-score and Z-score) less than -2.5 were accepted as osteoporosis and the scores between -1.5 and -2.5 were accepted as osteopenia. Patients were asked if they had any treatment for bone disorders. Results: Total 25 patients with thalasemia major (14 men, 11 women) were included to study. Patients average age was 22.0± 0.90 years. According to BMD scores 16 of our patients had osteoporosis where as 9 patients had osteopenia. None of the patients were screened for osteoporosis and also none of them was taken any supportive bone treatment. Conclusions: Patients with thalasemia major should be screened for osteoporosis which will affect their further life and quality of life and appropriate medications should be given at early stages.
Abstract (Original Language): 
Amac: Talasemilerin en agir tipi talasemi majordur. Talasemi ma-jorlu hastalarda anemi, hepatosplenomegali ve spinal deformiteler gibi kemik deformiteleri yaninda osteoporoz da gorulebilmekte-dir. Amacimiz talasemi major tanisi olan hastalarda osteoporoz sikligini degerlendirmektir. Yontem: Calismaya talasemi major tanisi alip takipte olan bireyler dahil edildi. Kemik mineral dansitesi T ve Z skorunun -2.5'in altinda olmasi osteoporoz, -1 ile -2.5 arasinda olmasi ise osteopeni olarak kabul edildi. Hastalarin osteoporoz agisindan tedavi alip almadiklari sorgulandi. Bulgular: Calismaya 14'u erkek, kadin toplam 25 talasemi major hastasi alindi. Hastalarin yas ortalamasi 22.0±0.90 yildi. Kemik mineral dansitesi skorlarina gore hastalarin 16'sinda hem Z hem de T skorlarina gore osteoporoz, 9 hastada ise osteopeni saptandi. Bu hastalarin higbirisine daha once osteoporoz taramasi yapilmamis ve herhangi bir destek tedavisi de baslanmamisti. Sonuc: Talasemi major hastalarinin kalan hayatlarini ve yasam ka-litesine olan etkileri agisindan kemik dansitometri ile taranmasinin ve uygun tedavilere en erken donemde baslanmasinin onemli ol-dugu gorusundeyiz.
153
156

REFERENCES

References: 

1. Yapici G, Kurt AO, Oner S, §a§maz T, Bugdayci R, Tamam A. Kronik kan transfuzyonu alan beta-talasemi major ve orak hucreli anemi hastalarinda gorulen komplikasyonlar. Cumhuriyet Tip Dergisi 2009;31:45-51.
2. Aksoy M, Lekin EW, Maurant AE, Lehmann H. Blood groups, hemoglo-bins,and thalassemia in Southern Turkey and Eti Turks. Br Med J 1958;
18;2:937-9.
3. Canatan D. Dunyada ve Turkiye'de talasemi ve anormal hemoglobinler http://www.talasemifederasyonu.org.tr/pdi^tani/1cansinTani.pdf / Eriflim
tarihi: 22.04.2013.
4. Perrotta S, Cappellini MD, Bertoldo F, et al. Osteoporosis in beta-thalas-saemia major patients: analysis of the genetic background. Br J Haematol
2000;111:461-6.
5. Jensen CE, Tuck SM, Agnew JE, et al. High incidence of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab 1998;11(Suppl 3):975-7.
6. Carmina E, Di Fede G, Napoli N, et al. Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassemia major. Calcif Tissue Int. 2004;74:68-71.
7. Vainas I. Bone mineral density of patients with thalassemia major: four-year follow-up. Calcif Tissue Int 1999;64:481-4.
8. Gulati R, Bhatia V, Agarwal SS. Early onset of endocrine abnormalities in beta-thalassemia major in a developing country. J Pediatr Endocrinol Metab
2000;13:651-6.
9. Morabito N, Lasco A, Gaudio A, et al. Bisphosphonates in the treatment of thalassemia-induced osteoporosis. OsteoporosInt 2002;13:644-9.
10. Perifanis V, Vyzantiadis T, Tziomalos K, et al. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with betathalassaemia. Ann Hematol2007;86:23-30.
11. Gaudio A, Morabito N, Xourafa A, et al. Bisphosphonates in the treat¬ment of thalassemia-associated osteoporosis. J Endocrinol Invest 2008;
31:181-4.
12. Trotta A, Corrado A, Cantatore FP. Anabolic therapy of induced osteo¬porosis in beta-thalassaemia major: case report and literature review. [Article in Italian] Reumatismo 2010;62:119-26.
13. Baytan B, Saglam H, Erdol ve ark. Talasemi majorlu vakalarda endok-rin komplikasyonlarin degerlendirilmesi. Giincel Pediatri 2008;6:58-65.
14. Mamtani M, Kulkarni H. Bone recovery after zoledronate therapy in tha-lassemia-induced osteoporosis: a meta-analysis and systematic review.
Osteoporos Int 2010;21:183-7.
Turkiye Aile Hekimligi Dergisi | Turkish Journal of Family Practice | Cilt 17 | Sayi 4 | 2013
155
15. Terpos E, Voskaridou E. Treatment options for thalassemia patients with
osteoporosis. Ann N Y Acad Sci 2010;1202:237-43.
16. Hatun S, Islam O, £izmecioglu F, et al. Subclinical vitamin D deficiency is increased in adolescent girls who wear concealing clothing. J Nutr
2005;135:218-22.
17. Kurt M, Comertoglu I, Sarp U, Yalgin P, Dinger G. Osteoporozlu hastalarda D vitamini duzeyleri. Tiirk Osteoporoz Dergisi 2011;17:68-70.
18. Haidar R, Musallam KM, Taher AT. Bone disease and skeletal complica¬tions in patients with, thalassemia major. Bone 2011;48:425-32.
19. Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M, Frisina N. Effects of hormonal replacement therapy on bone metabolism in young adults with beta thalassemia major. Osteoporos Int 2001;12:570-5.
20. Lindsay R. Prevention and treatment of osteoporosis. Lancet 1993;341:
801-5.
21. Soliman AT, El Banna N, Abdel Fattah M, El Zalabani MM, Ansari BM.
Bone mineral density in prepubertal children with beta-thalassemia: cor¬relation with growth and hormonal data. Metabolism 1998;47:541-8.
22. Toumba M, Skordis N. Osteoporosis syndrome in thalassaemia major: an
overview. J Osteoporos2010;2010:537673.
23. Gamberini MR, De Sanctis V, Gilli G. Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre. Pediatr Endocrinol Rev
2008;6(Suppl 1):158-69.

Thank you for copying data from http://www.arastirmax.com